Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06293898 · ClinicalTrials.gov registry record · Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by SystImmune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 17
- Study locations
NCT06293898: Recruiting Phase 1 study of Breast Cancer and Lung Cancer, sponsored by SystImmune.
NCT06293898 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by SystImmune. The registered enrollment target is 280 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06293898, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by SystImmune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 17
- Study locations
Study Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Primary Outcome
The number of patients with dose-limiting toxicities, serious adverse events, treatment-emergent adverse events, physical exam findings, vital signs, laboratory tests, ECG parameters and echocardiograph
Conditions Studied
Interventions
- DRUG BL-M07D1
Study Locations (17)
California
- City of Hope - Duarte
- Cedars Sinai - Los Angeles
- Scripps Health - San Diego
Florida
- University of Miami - Miami
- Sarah Cannon Research institute - Lake Nona Florida - Orlando
Illinois
- University of Illinois Cancer Center - Chicago
- University of Chicago Medicine - Chicago
New York
- NYU Langone Hospital - Long Island Investigational Pharmacy - Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Alabama
- University of Alabama Birmingham - Birmingham
Georgia
- Georgia Cancer Center at Augusta University - Augusta
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institiute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2024-02-09 |
| Est. Completion | 2029-04-15 |
| Phase | Phase 1 |
What NCT06293898 shows while recruiting
NCT06293898 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (90% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which BL-M07D1 is the first listed.
NCT06293898 lists 17 locations in 12 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT06293898 about?
NCT06293898 is a clinical study titled "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors". The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
What is the current status of trial NCT06293898?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2024-02-09. Estimated completion is 2029-04-15.
What conditions does trial NCT06293898 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer.
What interventions are being tested in trial NCT06293898?
The interventions under investigation include: BL-M07D1 (DRUG).
Who is sponsoring clinical trial NCT06293898?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06293898 being conducted?
This trial has 17 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06293898's enrollment target sits among peer trials
280 296th of 1224 higher than 927 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
- NCT05142189 · 280 participants · Phase 1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI